lifestyle.californiaconsumerbanking.com

Author: Zealand Pharma

Zealand Pharma Establishes U.S. Research Hub in Cambridge, Massachusetts to Expand Drug Discovery Capabilities and Accelerate Medicine Creation

May 4, 2026
Zealand Pharma to participate in upcoming investor conferences in March 2026

May 4, 2026
Zealand Pharma increases its share capital as a result of the exercise of employee warrants

May 3, 2026
Zealand Pharma announces positive Phase 2 results for petrelintide, an amylin analog with potential to redefine the weight management experience for people living with overweight and obesity

April 30, 2026
Resolutions from Zealand Pharma’s Annual General Meeting 2026

March 27, 2026
Zealand Pharma convenes its Annual General Meeting 2026

March 11, 2026
Zealand Pharma Announces Financial Results for the Full Year 2025

March 11, 2026
Zealand Pharma announces positive Phase 1a topline results with Kv1.3 channel blocker ZP9830

March 11, 2026
Zealand Pharma conference call on February 19 at 2pm CET (8am ET) to present full year 2025 financial results

March 10, 2026